title: Dose-finding study of paclitaxel and carboplatin in patients with advanced non-small cell lung cancer.
abstract: This dose-finding study was designed to determine the maximum tolerated dose (MTD), efficacy and toxicity of combined paclitaxel and carboplatin in 35 previously untreated patients with advanced non-small cell lung cancer (NSCLC). Paclitaxel was given as a 3-h infusion at escalating dose levels (100-250 mg/m2) immediately followed by carboplatin as a 30-min infusion (325 or 350 mg/m2) every 3 weeks. The dose-limiting toxicity, paresthesia, occurred at the highest dose level, therefore the recommended dose was established one level below (paclitaxel 225 mg/m2 with carboplatin 325 mg/m2). Neutropenia was the most common hematotoxicity; dose dependency was not apparent. Two patients, at different dose levels, had febrile neutropenia. Thrombocytopenia was rare. Non-hematological toxicities grade 3 or higher included infection, anorexia, alopecia and paresthesia. One patient had a hypersensitivity reaction (transient hypotension). The overall response rate was 23% and median survival time was 7.5 months. Promising activity and acceptable toxicity supports the development of this combination as a useful chemotherapeutic option in advanced NSCLC.
authors.affiliation: Centre Hospitalier Universitaire Avicenne, Oncology Department, Bobigny, France. jean-francois.morere@avc.ap-hop-paris.fr
authors.forename: J F
authors.initials: JF
authors.lastname: Morère
authors.forename: S
authors.initials: S
authors.lastname: Piperno-Neumann
authors.forename: M A
authors.initials: MA
authors.lastname: Coulon
authors.forename: F
authors.initials: F
authors.lastname: Vaylet
authors.forename: P
authors.initials: P
authors.lastname: L'Her
authors.forename: A
authors.initials: A
authors.lastname: Brunet
authors.forename: E
authors.initials: E
authors.lastname: Quinaux
authors.forename: J L
authors.initials: JL
authors.lastname: Breau
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000633:toxicity; D019540:Area Under Curve; D016190:Carboplatin / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000633:toxicity; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D017239:Paclitaxel / Q000008:administration & dosage* / Q000633:toxicity; D015996:Survival Rate
chemical_list: D016190:Carboplatin; D017239:Paclitaxel